ArticleFrontiers in neuroscience2025
Neuroprotective, eco-friendly iron oxide nanoparticles to alleviate Parkinson's disease symptoms and improve nursing care.
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Silicon quantum dots for neurotheranostic applications in dopamine detection.Journal of nanobiotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) involves motor impairment and neurochemical changes, necessitating neuroprotective agents to enhance nursing care outcomes. Methods: Iron oxide nanoparticles (IONPs) were biosynthesized via green chemistry and characterized by TEM, UV-Vis, photoluminescence, XRD, and VSM. Antioxidant activity used DPPH assay; biocompatibility involved MTT and hemolysis assays. Efficacy was tested in an MPTP-induced mouse model of PD, assessing motor function, antioxidant capacity, and dopaminergic neuron protection. Results: IONPs exhibited spherical morphology (39.0 ± 11.3 nm), zeta potential of -13 mV, and saturation magnetization of 42.32 emu/g. They showed concentration-dependent DPPH scavenging and no significant cytotoxicity or hemolysis up to 10 µg/mL. Conclusion: Biosynthesized IONPs offer promise as a complementary PD therapy by mitigating motor deficits and neurochemical damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.